Fukushima-shi, Japan
Fukushima-shi, Japan

Time filter

Source Type

Chikawa J.-I.,Hyogo Science and Technology Association | Mouri Y.,Himeji Health Center | Shima H.,Shima Institution for Quantum Medicine | Yamada K.,Hyogo Science and Technology Association | And 2 more authors.
Journal of X-Ray Science and Technology | Year: 2014

Time variations of elemental concentrations and their abnormalities due to breast cancer have been observed along single hair strands by X-ray fluorescence excited by synchrotron radiation. The renal-controlled elements Ca, Sr, S, K, Cl, Br and P have upper and lower levels associated with gating and closing of ion channels in the hair-making cells. The Ca lower level is normal. In cases of Ca deficiency, with a decrease from the normal, store-operated Ca channel gating occurs so as to keep the hair Ca at the normal, and paradoxically high Ca levels near or at the upper level are produced by PTH-operated channel gating of the cells. Chronic Ca deficiency shows a temporal pattern along the hair consisting of a long-term duration of the upper [Ca] level, 10-month long decay to the lower level and abrupt increase to the upper level. The observation for hair from breast-cancer patients also shows the upper Ca level for the time period well before detection, and suggests that cancer is always generated at the long-lasting [Ca] upper level and the hair [Ca] decreases gradually toward the lower level with the cancer growth. This decay of [Ca] is accompanied by those of [Sr] and [K]. Their different decay forms can be explained by parathyroid hormone related peptide (PTHrP) in serum secreted from the cancer having 150 times longer dwell time on the PTH receptors than that of PTH. Patient hair has a memory for the entire cancer process from the state before cancer generation, and the pattern can be distinguished from concentration variation due to the chronic Ca deficiency without cancer, leading to a criterion for cancer detection by the ratio of [Sr]/[Ca]. The hair analysis is useful for early detection of cancer. © 2014-IOS Press.


PubMed | Osaka Breast Clinic, Shima Institution for Quantum Medicine, Himeji Health Center, Hyogo Science and Technology Association and Hyogo College of Medicine
Type: Journal Article | Journal: Journal of X-ray science and technology | Year: 2014

Time variations of elemental concentrations and their abnormalities due to breast cancer have been observed along single hair strands by X-ray fluorescence excited by synchrotron radiation. The renal-controlled elements Ca, Sr, S, K, Cl, Br and P have upper and lower levels associated with gating and closing of ion channels in the hair-making cells. The Ca lower level is normal. In cases of Ca deficiency, with a decrease from the normal, store-operated Ca channel gating occurs so as to keep the hair Ca at the normal, and paradoxically high Ca levels near or at the upper level are produced by PTH-operated channel gating of the cells. Chronic Ca deficiency shows a temporal pattern along the hair consisting of a long-term duration of the upper [Ca] level, 10-month long decay to the lower level and abrupt increase to the upper level. The observation for hair from breast-cancer patients also shows the upper Ca level for the time period well before detection, and suggests that cancer is always generated at the long-lasting [Ca] upper level and the hair [Ca] decreases gradually toward the lower level with the cancer growth. This decay of [Ca] is accompanied by those of [Sr] and [K]. Their different decay forms can be explained by parathyroid hormone related peptide (PTHrP) in serum secreted from the cancer having 150 times longer dwell time on the PTH receptors than that of PTH. Patient hair has a memory for the entire cancer process from the state before cancer generation, and the pattern can be distinguished from concentration variation due to the chronic Ca deficiency without cancer, leading to a criterion for cancer detection by the ratio of [Sr]/[Ca]. The hair analysis is useful for early detection of cancer.


PubMed | Takeda Pharmaceutical, Kumamoto University, Osaka University, Kawasaki Medical School and 3 more.
Type: Journal Article | Journal: Breast cancer (Tokyo, Japan) | Year: 2016

Luteinizing hormone-releasing hormone (LH-RH) agonists provide effective adjuvant treatment for premenopausal women with endocrine-responsive breast cancer. Here, we investigated appropriate treatment durations of an LH-RH agonist, leuprorelin.We conducted an open-label, randomized controlled pilot study to evaluate the safety and efficacy of leuprorelin subcutaneously administered every-3-months for 2 versus 3 or more, up to 5 years, together with daily tamoxifen for 5 years in premenopausal endocrine-responsive breast cancer patients. Primary endpoints were disease-free survival (DFS) and safety.Eligible patients (N = 222) were randomly assigned to receive leuprorelin for either 2 years (N = 112) or 3 or more years (N = 110) with tamoxifen for 5 years after surgery. Leuprorelin treatment for 3 or more years provided no significant difference in DFS rate over 2 years: 94.1 versus 91.8 % at 144 weeks (3 years) after the second year (week 96) and 90.8 versus 90.4 % at the fifth year (week 240). The overall survival rate was 100 % for both groups during the third through fifth year study period. There were no significant differences in the incidence of adverse events (AEs) between the 2 groups: most AEs were rated grade 1 or 2.Adjuvant leuprorelin treatment for 3 or more years with tamoxifen showed a survival benefit and safety profile similar to that for 2 years in premenopausal endocrine-responsive breast cancer patients. No new safety signal was identified for long-term leuprorelin treatment. Longer follow-up observation is needed to determine the optimal duration of leuprorelin treatment.


Ooe A.,Osaka Breast Clinic | Takahara S.,Kitano Hospital | Sumiyoshi K.,Osaka Breast Clinic | Yamamoto H.,Osaka Breast Clinic | And 2 more authors.
Breast Disease | Year: 2012

BACKGROUND: For locally advanced breast cancer, neoadjuvant chemotherapy (NAC) is the standard of care for downstaging the tumor prior to surgery, and improved prognoses that are associated with pathological complete responses (pCR) have been noted, particularly in patients with human epidermal growth factor receptor 2 (HER2)-positive and triple negative (TN) tumors. OBJECTIVE: The aim of this study was to assess the differences in pathological responses among intrinsic subtypes of local lesions and status of axillary lymph nodes (Ax LN). METHODS: A consecutive series of 134 patients with locally advanced breast cancer who were treated with NAC was analyzed. Tumors were classified into the following 5 subtypes according to immunohistochemical staining results: Luminal A type, Luminal B type (HER2-negative and HER2-positive), HER2 type, and TN type. RESULTS: In Luminal A, Luminal B (HER2-negative), Luminal B (HER2-positive), HER2, and TN tumors, the pCR rates were 10% (4 of 40), 19% (8 of 42), 42% (8 of 19), 59% (10 of 17), and 38% (6 of 16), respectively. HER2-positive tumors showed good therapeutic effects, while Luminal A tumors showed less therapeutic effects. CONCLUSIONS: Strategies that are determined according to intrinsic subtypes are becoming very important in the treatment of locally advanced breast cancer. © 2012/2013-IOS Press and the authors.


PubMed | Osaka Breast Clinic
Type: Case Reports | Journal: Japanese journal of clinical oncology | Year: 2011

Fibroadenoma is the most common form of benign breast tumor and the most common breast tumor in women under 30 years of age. However, carcinoma arising within a fibroadenoma is unusual, with over 100 cases reported in the literature. Histological diagnosis is typically unexpected. A 46-year-old female with no family history of breast malignancies was admitted for an elastic hard lump in the upper-outer quadrant of her right breast. At a clinic that she visited previously, her condition was diagnosed by core needle biopsy with four specimens showing fibroadenoma with borderline atypical ductal hyperplasia at pathology. Excisional biopsy was recommended for pathological diagnosis. The patient requested a definitive diagnosis and alternative treatment to tumorectomy. More biopsy specimens were needed for pathological diagnosis; therefore, ultrasonography-guided vacuum-assisted core needle biopsies were obtained, confirming ductal carcinoma in situ with questionable microinvasion of intracanalicular- and pericanalicular-type fibroadenoma. Right breast-conserving surgery and sentinel lymph node biopsy were immediately performed for radical therapy. We present this case to increase awareness of this entity and stress the need for histological evaluation of some breast masses.


PubMed | Osaka Breast Clinic
Type: Journal Article | Journal: Breast disease | Year: 2013

For locally advanced breast cancer, neoadjuvant chemotherapy (NAC) is the standard of care for downstaging the tumor prior to surgery, and improved prognoses that are associated with pathological complete responses (pCR) have been noted, particularly in patients with human epidermal growth factor receptor 2 (HER2)-positive and triple negative (TN) tumors.The aim of this study was to assess the differences in pathological responses among intrinsic subtypes of local lesions and status of axillary lymph nodes (Ax LN).A consecutive series of 134 patients with locally advanced breast cancer who were treated with NAC was analyzed. Tumors were classified into the following 5 subtypes according to immunohistochemical staining results: Luminal A type, Luminal B type (HER2-negative and HER2-positive), HER2 type, and TN type.In Luminal A, Luminal B (HER2-negative), Luminal B (HER2-positive), HER2, and TN tumors, the pCR rates were 10% (4 of 40), 19% (8 of 42), 42% (8 of 19), 59% (10 of 17), and 38% (6 of 16), respectively. HER2-positive tumors showed good therapeutic effects, while Luminal A tumors showed less therapeutic effects.Strategies that are determined according to intrinsic subtypes are becoming very important in the treatment of locally advanced breast cancer.

Loading Osaka Breast Clinic collaborators
Loading Osaka Breast Clinic collaborators